| Literature DB >> 28880941 |
Maria Romøren1,2, Svein Gjelstad2, Morten Lindbæk2.
Abstract
OBJECTIVES: Hospitalization is potentially detrimental to nursing home patients and resource demanding for the specialist health care. This study assessed if a brief training program in administrating intravenous fluids and antibiotics in nursing homes could reduce hospital transfers and ensure high quality care locally.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28880941 PMCID: PMC5589147 DOI: 10.1371/journal.pone.0182619
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1CONSORT 2010 checklist of information to include when reporting a cluster randomised trial.
Suggested modifications to the CONSORT 2010 cluster extension for reporting of stepped wedge cluster randomised trials.
Fig 2Modified stepped-wedge design with 30 clusters (nursing homes).
Each cluster receive the intervention at baseline. The median length of the steps (intervals between each crossover) was 14 days (0–171 days).
Characteristics of patients provided intravenous antibiotics or fluids in nursing homes and hospital, by control and intervention group.
Values are numbers (percentages) unless stated otherwise. Calculation of p-values was done by independent samples T-test (two-sided) for comparing means, and two-sided chi-square test for comparing differences in counts.
| Control | Intervention | Total | P-values | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nursing home (n = 38) | Hospital (n = 64) | Total (n = 102) | Nursing home (n = 184) | Hospital (n = 44) | Total (n = 228) | n = 330 | Control vs. intervention | Nursing home vs.hospital | ||
| 79,6 | 81,8 | 81,0 | 81,0 | 83,9 | 81,6 | 81,4 | 0.02 | 0.11 | ||
| 81.0 | 85.0 | 84.0 | 83.0 | 85.5 | 84.0 | 84.0 | 0.02 | 0.11 | ||
| 28 (73) | 41 (64) | 69 (69) | 98 (53) | 21 (48) | 119 (52) | 188 (57) | < | 0.91 | ||
| Mean | 6,2 | 6,6 | 6.5 | 0.72 | N/A | |||||
| 7,9 | 8,4 | 8,2 | 8,6 | 9,0 | 8,7 | 8,5 | 0.31 | 0.80 | ||
| Apoplexia (n = 271) | 5 (32) | 20 (33) | 25 (32) | 32 (22) | 12 (27) | 44(23) | 69 (26) | 0.11 | 0.18 | |
| COPD (n = 271) | 3 (21) | 16 (25) | 19 (24) | 28 (19) | 14 (33) | 42 (22) | 61 (23) | 0.59 | 0.08 | |
| Angina pectoris (n = 270) | 7 (50) | 17 (27) | 24 (31) | 33 (22) | 18 (41) | 51 (26) | 75 (28) | 0.43 | 0.14 | |
| Heart failure (n = 270) | 4 (29) | 22 (35) | 26 (34) | 35 (24) | 27 (61) | 62 (32) | 88 (33) | 0.80 | < | |
| Diabetes (n = 271) | 1 (7) | 15 (24) | 16 (21) | 21 (14) | 7 (16) | 28 (14) | 44 (16) | 0.20 | 0.12 | |
| Cancer (n = 270) | 3 (21) | 10 (16) | 13 (17) | 62 (42) | 12 (27) | 74 (38) | 87 (32) | < | < | |
| Pneumonia | 13 (65) | 26 (54) | 39 (57) | 63 (70) | 21 (58) | 84 (67) | 123 (63) | 0.20 | 0.06 | |
| Pneumonia & urinary tract infect. | 3 (15) | 13 (27) | 16 (24) | 7 (8) | 8 (22) | 15 (12) | 31 (16) | < | ||
| Upper urinary tract infection | 3 (15) | 7 (15) | 10 (15) | 10 (11) | 6 (17) | 16 (13) | 26 (13) | 0.70 | 0.46 | |
| Other infections | 1 (5) | 2 (4) | 3 (4) | 10 (11) | 1 (3) | 11 (9) | 14 (7) | 0.27 | 0.09 | |
| Infection (with/wthout registered reduced intake, hypotension etc) | 13 (72) | 10 (63) | 23 (68) | 66 (70) | 6 (75) | 72 (71) | 95 (70) | 0.75 | 0.71 | |
| No infection (reduced intake, hypotension etc.) | 5 (28) | 6 (38) | 11 (32) | 28 (30) | 2 (25) | 30 (29) | 41 (30) | - | - | |
| Systolic BP (mean/median) | 120/109 | 138/130 | 132/125 | 122/120 | 140/137 | 127/124 | 125/123 | 0.06 | < | |
| Pulse (mean/median) | 92/99 | 93/88 | 93/88 | 84/86 | 90/85 | 86/85 | 87/85 | 0.30 | ||
| Respiratory rate (mean/median) | 18/18 | 22/22 | 21/20 | 21/20 | 23/20 | 21/20 | 21/20 | 0.72 | 0.24 | |
| Temp (mean/median) | 37.5/37.2 | 37.6/37.7 | 37.6/37.6 | 37.5/37.2 | 37.3/37.3 | 37.5/37.3 | 37.5/37.4 | 0.46 | 0.31 | |
| Septicemia score > 2 | 1 (3) | 4 (6) | 5 (5) | 7 (4) | 3 (7) | 10 (4) | 15(5) | 0.84 | 0.24 | |
| Reduced consciousness | 22 (58) | 18 (28) | 40 (39) | 83 (45) | 15 (43) | 98 (43) | 138 (42) | 0.52 | < | |
| CRP-value (mean/median) | 79/63 | 132/132 | 116/124 | 108/97 | 152/178 | 119/101 | 111/101 | 0.55 | < | |
| Reduced food intake | 35 (92) | 54 (84) | 89 (87) | 164 (89) | 39 (89) | 203 (89) | 292 (89) | 0.64 | 0.35 | |
| Reduced fluid intake | 34 (90) | 57 (89) | 91 (89) | 165 (90) | 39 (89) | 204 (90) | 295 (89) | 0.94 | 0.84 | |
| Delirium | 4 (11) | 15 (23) | 19 (19) | 27 (15) | 7 (16) | 34 (15) | 53 (16) | 0.43 | 0.17 | |
*Skin, gastrointestinal and unspecified infections
Fig 3Flowchart showing nursing home and patient recruitment.
Patients that did not fill the inclusion criteria, or patients who by mistake were eligible, but not included, were not registered. All eligible patients consented to participate and no patients were excluded. None of the included patients were lost during the 30 days follow up; death in the period was regarded as an outcome.
Number of patients provided intravenous treatments in nursing home or hospital and treatments per 100 beds per month in each of the 30 nursing homes in Vestfold, Norway in the study period 2009–2011.
| Control period | Intervention period | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nursing home | Treatmentsper 100beds/month | Hospital | Nursing home | Treatments per 100beds/month | |||||||
| Nursing home no. | Number of beds | No. iv ab | No. iv fluids | No. iv ab | No. iv fluids | No. iv ab | No. iv fluids | No. iv ab | No. iv fluids | |||
| 124 | 0 | 0 | 0 | 0 | - | 3 | 1 | 14 | 11 | 0.90 | 29 | |
| 122 | 0 | 0 | 0 | 0 | 5 | 1 | 42 | 40 | 2.77 | 88 | ||
| 19 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 6 | 1.42 | 7 | |
| 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0.76 | 4 | |
| 48 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 4 | 5 | 1.04 | 12 | |
| 38 | 0 | 0 | 1 | 0 | 0.66 | 1 | 0 | 1 | 4 | 0.72 | 7 | |
| 12 | 1 | 0 | 0 | 0 | 2.08 | 1 | 0 | 0 | 1 | 0.76 | 3 | |
| 68 | 1 | 0 | 0 | 0 | 0.29 | 5 | 0 | 0 | 3 | 0.56 | 9 | |
| 26 | 5 | 0 | 0 | 1 | 4.62 | 3 | 1 | 4 | 1 | 1.65 | 15 | |
| 16 | 1 | 0 | 0 | 0 | 1.04 | 1 | 0 | 0 | 1 | 0.63 | 3 | |
| 69 | 2 | 2 | 3 | 0 | 1.69 | 2 | 0 | 3 | 2 | 0.51 | 14 | |
| 28 | 3 | 1 | 0 | 1 | 1.79 | 1 | 0 | 1 | 1 | 0.67 | 8 | |
| 20 | 0 | 0 | 0 | 1 | 0.45 | 0 | 1 | 0 | 0 | 0.33 | 2 | |
| 16 | 3 | 0 | 0 | 0 | 1.56 | 0 | 1 | 4 | 1 | 2.68 | 9 | |
| 86 | 1 | 0 | 2 | 1 | 0.39 | 4 | 0 | 1 | 1 | 0.50 | 10 | |
| 18 | 0 | 0 | 0 | 2 | 0.93 | 0 | 0 | 0 | 1 | 0.40 | 3 | |
| 32 | 2 | 2 | 0 | 1 | 1.30 | 0 | 0 | 8 | 1 | 2.01 | 14 | |
| 58 | 3 | 0 | 0 | 0 | 0.34 | 1 | 0 | 0 | 4 | 0.78 | 8 | |
| 64 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0.14 | 1 | |
| 52 | 4 | 5 | 0 | 0 | 1.15 | 0 | 0 | 0 | 0 | 0 | 9 | |
| 33 | 0 | 0 | 1 | 0 | 0.19 | 1 | 0 | 1 | 0 | 0.61 | 3 | |
| 20 | 4 | 0 | 1 | 2 | 2.19 | 1 | 2 | 0 | 2 | 2.50 | 12 | |
| 76 | 3 | 1 | 0 | 0 | 0.33 | 1 | 0 | 0 | 1 | 0.26 | 6 | |
| 25 | 2 | 1 | 0 | 0 | 0.71 | 1 | 0 | 0 | 0 | 0.44 | 4 | |
| 48 | 0 | 1 | 2 | 0 | 0.37 | 0 | 0 | 0 | 0 | 0 | 3 | |
| 56 | 3 | 0 | 10 | 3 | 1.59 | 0 | 1 | 5 | 3 | 2.01 | 25 | |
| 46 | 2 | 2 | 0 | 0 | 0.48 | 1 | 0 | 0 | 1 | 0.54 | 6 | |
| 38 | 2 | 1 | 0 | 0 | 0.44 | 0 | 0 | 0 | 0 | 0 | 3 | |
| 55 | 4 | 0 | 0 | 0 | 0.32 | 0 | 0 | 0 | 1 | 0.61 | 5 | |
| 44 | 2 | 0 | 0 | 6 | 0.76 | 0 | 0 | 0 | 0 | 0 | 8 | |
| 1 379 | 48 | 16 | 20 | 18 | 0.86 | 36 | 8 | 90 | 94 | 0.87 | 330 | |
Number of patients receiving intravenous antibiotics and fluids in hospital versus nursing home in the intervention and control group.
Values are numbers (percentages). The calculated p-values are adjusted for clustering at the nursing home level.
| Control | Intervention | P-values | |||
|---|---|---|---|---|---|
| n | (%) | n | (%) | ||
| Nursing home | 20 | (29) | 90 | (71) | |
| Hospital | 48 | (71) | 36 | (29) | |
| Total | 68 | (100) | 126 | (100) | <0.05 |
| Nursing home | 18 | (53) | 94 | (92) | |
| Hospital | 16 | (47) | 8 | (8) | |
| Total | 34 | (100) | 102 | (100) | <0.05 |
| Nursing | 38 | (37) | 184 | (81) | |
| Hospital | 64 | (63) | 44 | (19) | |
| Total | 102 | (100) | 228 | (100) | <0.05 |
Fig 4Number of patients receiving intravenous antibiotics and fluids in nursing home versus hospital in the study period, per 3 months.
Associations of demographic and clinical variables with intravenous treatment in the nursing home.
Multilevel logistic regression model with nursing home as cluster (random intercept).
| Factors | Bivariate analysis | Multivariate analysis (N = 249) | ||||
|---|---|---|---|---|---|---|
| OR | (95% CI) | P-value | OR | (95% CI) | P-value | |
| 5.60 | 2.79 to 11.2 | <0.01 | 8.35 | 2.08 to 33.6 | <0.01 | |
| 0.18 | 0.09 to 0.36 | <0.01 | 0.89 | 0.31 to 2.54 | 0.82 | |
| 0.69 | 0.38 to 1.23 | 0.21 | 0.95 | 0.39 to 2.29 | 0.90 | |
| 3.21 | 1.71 to 6.05 | <0.01 | 2.12 | 0.84 to 5.38 | 0.11 | |
| <115 mmHg | Reference | Reference | ||||
| 115 to 138 mmHg | 0.65 | 0.31 to 1.37 | 0.26 | 0.84 | 0.27 to 2.56 | 0.75 |
| >138 mmHg | 0.33 | 0.16 to 0.67 | <0.01 | 0.33 | 0.11 to 2.56 | 0.04 |
| <65 | Reference | Reference | ||||
| 65 to 156 | 0.78 | 0.36 to 1.67 | 0.52 | 0.75 | 0.24 to 2.33 | 0.62 |
| >156 | 0.25 | 0.11 to 0.57 | <0.01 | 0.20 | 0.06 to 0.73 | 0.02 |
| 0.20 | 0.09 to 0.42 | <0.01 | 0.15 | 0.06 to 0.42 | <0.01 | |
| 1 to 5 | Reference | Reference | ||||
| 6 to 10 | 0.57 | 0.21 to 1.54 | 0.27 | 0.67 | 0.11 to 3.94 | 0.66 |
| 11 to 15 | 1.30 | 0.49 to 3.43 | 0.60 | 1.74 | 0.31 to 9.73 | 0.53 |
| 16 to 20 | 0.45 | 0.15 to 1.29 | 0.14 | 0.53 | 0.09 to 3.05 | 0.48 |
| 21 to 25 | 4.46 | 1.11 to 17.9 | 0.04 | 6.59 | 0.58 to 75.5 | 0.13 |
| 26 to 30 | 3.83 | 1.27 to 11.5 | 0.02 | 2.47 | 0.35 to 17.5 | 0.36 |
Associations of demographic and clinical variables with 30-day mortality in patients provided intravenous treatment in nursing homes and hospital.
Multilevel logistic regression model with nursing home as cluster (random intercept).
| Bivariate analysis | Multivariate analysis (n = 249) | |||||
|---|---|---|---|---|---|---|
| OR | (95% CI) | P-value | OR | (95% CI) | P-value | |
| 1.49 | 0.88 to 2.51 | 0.14 | 1.22 | 0.50 to 3.05 | 0.66 | |
| 1.12 | 0.68 to 1.84 | 0.67 | 1.43 | 0.64 to 3.23 | 0.39 | |
| 3.54 | 2.05 to 6.11 | <0.01 | 2.79 | 1.23 to 6.30 | 0.01 | |
| 1.10 | 0.69 to 1.76 | 0.69 | 1.03 | 0.56 to 1.90 | 0.92 | |
| <70 | Reference | Reference | ||||
| 70 to 79 | 0.31 | 0.13 to 0.70 | <0.01 | 0.17 | 0.57 to 0.52 | <0.01 |
| 80 to 89 | 0.42 | 0.20 to 0.88 | 0.02 | 0.37 | 0.13 to 1.04 | 0.06 |
| >90 | 0.37 | 0.16 to 0.88 | 0.02 | 0.37 | 0.12 to 1.14 | 0.08 |
| 0.22 | 0.72 to 2.09 | 0.46 | 1.41 | 0.72 to 2.77 | 0.32 | |
| 2.14 | 1.31 to 3.47 | <0.01 | 2.61 | 1.41 to 4.83 | <0.01 | |
| <115 mmHg | Reference | Reference | ||||
| 115 to 138 mmHg | 0.87 | 0.50 to 1.53 | 0.63 | 1.28 | 0.61 to 2.68 | 0.52 |
| >138 mmHg | 0.71 | 0.39 to 1.27 | 0.25 | 0.93 | 0.43 to 2.00 | 0.86 |
| <65 | Reference | Reference | ||||
| 65 to 156 | 1.28 | 0.67 to 2.44 | 0.46 | 0.86 | 0.39 to 1.93 | 0.72 |
| >156 | 2.98 | 1.59 to 5.57 | <0.01 | 1.84 | 0.82 to 4.15 | 0.14 |
| 1 to 5 | Reference | Reference | ||||
| 6 to 10 | 0.53 | 0.22 to 1.25 | 0.15 | 0.54 | 0.17 to 1.68 | 0.29 |
| 11 to 15 | 1.41 | 0.65 to 3.06 | 0.38 | 1.86 | 0.64 to 5.42 | 0.26 |
| 16 to 20 | 0.70 | 0.33 to 1.47 | 0.34 | 0.67 | 0.24 to 1.89 | 0.45 |
| 21 to 25 | 0.76 | 0.31 to 1.87 | 0.56 | 0.95 | 0.25 to 3.57 | 0.94 |
| 26 to 30 | 0.73 | 0.35 to 1.52 | 0.40 | 0.71 | 0.22 to 2.32 | 0.57 |
Choice of antibiotics in nursing homes versus hospital to patients provided intravenous and oral antibiotics, by diagnosis.
| Benzylpenicillin | 26 (34) | 1 (10) | 0 | 2 (18) | 23 (49) | 4 (19) | 0 | 0 | 56 (29) |
| Broad spectrum penicillin | 1 (1) | 1 (10) | 0 | 0 | 3 (6) | 1 (5) | 2 (15) | 0 | 8 (4) |
| Cefalosporins | 43 (57) | 8 (80) | 12 (92) | 7 (64) | 17 (36) | 12 (57) | 10 (77) | 1 (33) | 110 (57) |
| Other iv antibiotics | 2 (3) | 0 | 1 (8) | 0 | 0 | 1 (5) | 0 | 0 | 4 (2) |
| Combinations | 4 (5) | 0 | 0 | 2 (18) | 4 (9) | 3 (14) | 1 (8) | 2 (67) | 16 (8) |
| Total | 76 (100) | 10 (100) | 13 (100) | 11 (100) | 47 (100) | 21 (100) | 13 (100) | 3 (100) | 194 (100) |
| Phenoxymetylpenicillin | 6 (30) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 (12) |
| Broad spectrum penicillin | 10 (50) | 1 (33) | 8 (50) | 2 (40) | 1 (50) | 0 | 2 (40) | 0 | 24 (46) |
| Ciprofloxacin | 1 (5) | 0 | 4 (25) | 0 | 0 | 1 (100) | 3 (60) | 0 | 9 (17) |
| Doksycyclin | 3 (15) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (6) |
| Nitrofuradantin | 0 | 0 | 2 (13) | 0 | 0 | 0 | 0 | 0 | 2 (4) |
| Trimetoprim +/- sulfa | 0 | 1 (33) | 1 (6) | 0 | 1 (50) | 0 | 0 | 0 | 3 (6) |
| Other oral antibiotics | 0 | 1 (33) | 1 (6) | 3 (60) | 0 | 0 | 0 | 0 | 5 (10) |
| Total | 20 (100) | 3 (100) | 16 (100) | 5 (100) | 2 (100) | 1 (100) | 5 (100) | 0 | 52 (100) |
*Other: skin, gastrointestinal and unspecified infections;
**Other iv antibiotics: ciprofloxacin (n = 1), meropenem (n = 3);
***Combinations: cefotaksim + benzylpenicillin/metronidazol/meropenem/klindamycin (n = 9), gentamicin + benzylpenicillin/ampicillin (n = 5), klindamycin + benzylpenicillin (n = 2);
****Other oral antibiotics: cefotaksim (n = 1), erythromycin (n = 1), metronidazol (n = 2), vancomycin (n = 1).